Ascentage Pharma Group International (HK:6855)
:6855
Want to see HK:6855 full AI Analyst Report?
Total Valuation
Ascentage Pharma Group International has a market cap or net worth of HK$15.65B. The enterprise value is HK$13.17B.
Market CapHK$15.65B
Enterprise ValueHK$13.17B
Share Statistics
Ascentage Pharma Group International has 373,322,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding373,322,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Ascentage Pharma Group International’s return on equity (ROE) is -0.91 and return on invested capital (ROIC) is -33.32%.
Return on Equity (ROE)-0.91
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-33.32%
Return on Capital Employed (ROCE)-0.51
Revenue Per Employee986.35K
Profits Per Employee-2.18M
Employee Count567
Asset Turnover0.14
Inventory Turnover4.61
Valuation Ratios
The current PE Ratio of Ascentage Pharma Group International is ―. Ascentage Pharma Group International’s PEG ratio is -0.09.
PE Ratio―
PS Ratio29.89
PB Ratio12.61
Price to Fair Value12.61
Price to FCF-13.91
Price to Operating Cash Flow-11.21
PEG Ratio-0.09
Income Statement
In the last 12 months, Ascentage Pharma Group International had revenue of 559.26M and earned -1.21B in profits. Earnings per share was -3.40.
Revenue559.26M
Gross Profit427.35M
Operating Income-1.18B
Pretax Income-1.20B
Net Income-1.21B
EBITDA-1.10B
Earnings Per Share (EPS)-3.40
Cash Flow
In the last 12 months, operating cash flow was -1.21B and capital expenditures -27.82M, giving a free cash flow of -1.24B billion.
Operating Cash Flow-1.21B
Free Cash Flow-1.24B
Free Cash Flow per Share-3.33
Dividends & Yields
Ascentage Pharma Group International pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.80
52-Week Price Change-11.59%
50-Day Moving Average47.03
200-Day Moving Average63.81
Relative Strength Index (RSI)62.37
Average Volume (3m)2.29M
Important Dates
Ascentage Pharma Group International upcoming earnings date is Aug 25, 2026, TBA (Confirmed).
Last Earnings DateMar 25, 2026
Next Earnings DateAug 25, 2026
Ex-Dividend Date―
Financial Position
Ascentage Pharma Group International as a current ratio of 1.79, with Debt / Equity ratio of 149.47%
Current Ratio1.79
Quick Ratio1.77
Debt to Market Cap0.12
Net Debt to EBITDA0.45
Interest Coverage Ratio-22.42
Taxes
In the past 12 months, Ascentage Pharma Group International has paid 6.76M in taxes.
Income Tax6.76M
Effective Tax Rate>-0.01
Enterprise Valuation
Ascentage Pharma Group International EV to EBITDA ratio is -14.79, with an EV/FCF ratio of -13.50.
EV to Sales29.01
EV to EBITDA-14.79
EV to Free Cash Flow-13.50
EV to Operating Cash Flow-13.82
Balance Sheet
Ascentage Pharma Group International has HK$2.47B in cash and marketable securities with HK$1.98B in debt, giving a net cash position of HK$490.58M billion.
Cash & Marketable SecuritiesHK$2.47B
Total DebtHK$1.98B
Net CashHK$490.58M
Net Cash Per ShareHK$1.31
Tangible Book Value Per ShareHK$3.49
Margins
Gross margin is 84.09%, with operating margin of -211.14%, and net profit margin of -216.47%.
Gross Margin84.09%
Operating Margin-211.14%
Pretax Margin-215.29%
Net Profit Margin-216.47%
EBITDA Margin-196.08%
EBIT Margin-211.14%
Analyst Forecast
The average price target for Ascentage Pharma Group International is HK$80.10, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$80.10
Price Target Upside57.37% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-41.32%
EPS Growth Forecast-159.81%